Health
Moderna’s stock has surged 488% in 2020: Is it a buy for 2021? – Motley Fool Australia
This smaller biotech company attracted a lot of attention in 2020, but is it still worth an investment?
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
All eyes were on the biotech Moderna(NASDAQ: MRNA) in 2020. It wasn’t quite a popular name in the pharmaceutical space, as it has no approved products on the market yet. But its sudden entry in the COVID-19 vaccine competition grabbed a lot of attention, and it became the second company to win approval in a race with dozens of players. No wonder its stock has surged 488% so far this year,…
-
Business23 hours agoZip shares rocketed 32% in August. Here’s how
-
Business21 hours agoDown more than 20% this year, does Macquarie rate Boss Energy shares a buy?
-
General22 hours agoKids unknowingly targeted with AI abuse apps, images
-
Noosa News21 hours agoThe small patch of paddock emitting 10,000 cars’ worth of methane